London, 19 August 2015 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today reports its interim results for the six months ended 30 June 2015.
H1 2015 financial highlights
Group revenue of $709 million, in line with H1 2014 in constant currency1, or down 4% on a reported basis, with good performances from Branded and Injectables, offset by the expected decline in specific market opportunities in Generics
Full year Group revenue guidance maintained at around 6% growth in constant currency, or 2% on a reported basis
Group adjusted operating profit of $204 million, compared with $244 million in H1 2014,
Basic EPS of 67.3 cents per share, down 21%
Interim dividend of 11.0 cents per share, in line with total dividend paid in H1 2014
For full access, please click here.
Help employers find you! Check out all the jobs and post your resume.
